Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Alterations
NCT05315700Phase 2Recruiting
- Sponsor
- ORIC Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of enozertinib in solid tumor (2 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 12 months, Maximum plasma concentration at 28 Days and 3 more. Started Mar 2022; status: recruiting.
02
Drugs
enozertinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05315700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315700.